These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas]. Zhang X; Wang Y; Gao N; Wang J Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565 [TBL] [Abstract][Full Text] [Related]
31. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. Balschun K; Haag J; Wenke AK; von Schönfels W; Schwarz NT; Röcken C J Mol Diagn; 2011 Jul; 13(4):436-45. PubMed ID: 21704278 [TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711 [TBL] [Abstract][Full Text] [Related]
33. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059 [TBL] [Abstract][Full Text] [Related]
35. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. Shimizu Y; Maruyama K; Suzuki M; Kawachi H; Low SK; Oh-Hara T; Takeuchi K; Fujita N; Nagayama S; Katayama R Cancer Lett; 2022 Sep; 543():215799. PubMed ID: 35724767 [TBL] [Abstract][Full Text] [Related]
36. Genomic Profiling of Stage II Colorectal Cancer Identifies Candidate Genes Associated with Recurrence-Free Survival, Tumor Location, and Differentiation Grade. Dimberg J; Andersson RE; Haglund S Oncology; 2020; 98(8):575-582. PubMed ID: 32408300 [TBL] [Abstract][Full Text] [Related]
37. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936 [TBL] [Abstract][Full Text] [Related]
38. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder. Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892 [TBL] [Abstract][Full Text] [Related]
39. Longitudinal molecular characterization of endoscopic specimens from colorectal lesions. Minarikova P; Benesova L; Halkova T; Belsanova B; Suchanek S; Cyrany J; Tuckova I; Bures J; Zavoral M; Minarik M World J Gastroenterol; 2016 May; 22(20):4936-45. PubMed ID: 27239120 [TBL] [Abstract][Full Text] [Related]
40. High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer. Lee SE; Park HY; Hwang DY; Han HS Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074070 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]